BTM Nanodesign offers a patented technology that can improve any antibody purification application. Due to the small diameter of our protein nanofibrils – the diameter is 10,000 times thinner than a human hair – they generate a large surface area over volume ratio. This implies that our protein nanofibrils, can display many more antibody binding domains in a given volume, than other materials.

In general, monoclonal antibodies are a new class of medication that aim to activate the innate immune systems, in order to reduce common side effects that are typical for small compound drugs. The demand for these therapeutically antibodies increases at an astonishing rate, which requires new, faster and cheaper ways to purify them. A possible solution to this new demand are BTM Nanodesign’s antibody binding fibrils that have a 5-time increased binding capacity, compared to any existing commercially available product.